A Tonic Signaling Code Predicts CAR-T Cell Efficacy in Diffuse Midline Glioma.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Diffuse midline glioma (DIPG/DMG) is a fatal pediatric brain tumor with limited treatment options.
• CAR T-cell therapy shows promise but faces challenges like limited persistence and premature exhaustion.
• Current biomarkers for CAR T-cell exhaustion or stemness have shown limited utility.

Purpose of the Study:

• To systematically compare CAR T-cell constructs targeting B7-H3 for DIPG treatment.
• To identify key determinants of CAR T-cell therapeutic performance.
• To develop a predictive framework for CAR T-cell therapy efficacy.

Main Methods:

• Systematic comparison of multiple CAR T-cell constructs targeting B7-H3.
• Assessment of CAR T-cell performance in patient-derived DIPG models.
• Integrated multi-omics and single-cell profiling to identify predictive gene signatures.

Main Results:

• Restrained tonic signaling in B7-H3 CAR T-cells led to superior tumor killing, persistence, and resistance to exhaustion.
• Reduced CAR membrane clustering was observed in CAR T-cells with restrained tonic signaling.
• A CAR-T tonic signaling-associated gene signature effectively predicted therapeutic efficacy across multiple clinical trials.

Conclusions:

• Antigen-independent CAR activation (tonic signaling) is a critical determinant of CAR T-cell efficacy.
• Modulating tonic signaling offers a strategy to enhance CAR T-cell therapy for DIPG and other cancers.
• The identified gene signature provides a valuable tool for predicting CAR T-cell therapy outcomes.